Preferred Label : aminopyridines;

MeSH definition : Pyridines substituted in any position with an amino group. May be hydrogenated, but must retain at least one double bond.; Pyridines substituted in any position with an amino group. May be hydrogenated but must retain at least one double bond.;

MeSH synonym : Aminopyridine;

MeSH annotation : pyridinamines & pyridylamines;

Wikipedia link : https://en.wikipedia.org/wiki/Aminopyridine;

Is substance : O;

Details


Main resources

You can consult :

Pyridines substituted in any position with an amino group. May be hydrogenated, but must retain at least one double bond.
Pyridines substituted in any position with an amino group. May be hydrogenated but must retain at least one double bond.

https://www.has-sante.fr/jcms/p_3237418/fr/verzenios-abemaciclib
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
abemaciclib
antineoplastic combined chemotherapy protocols
postmenopause
breast neoplasms
antineoplastic agents
administration, oral
neoplasm metastasis
Abemaciclib/Fulvestrant Regimen
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
evaluation of the transparency committee
abemaciclib
aminopyridines
benzimidazoles

---
https://www.has-sante.fr/jcms/p_3229924/fr/kisqali
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
ribociclib
ribociclib
Ribociclib Succinate
antineoplastic combined chemotherapy protocols
Fulvestrant/Ribociclib Regimen
Fulvestrant
antineoplastic agents
breast neoplasms
postmenopause
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
protein kinase inhibitors
evaluation of the transparency committee
aminopyridines
purines

---
https://www.has-sante.fr/jcms/p_3199713/fr/kisqali
2020
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
administration, oral
ribociclib
ribociclib
antineoplastic combined chemotherapy protocols
breast neoplasms
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
antineoplastic agents
protein kinase inhibitors
treatment outcome
aminopyridines
purines

---
https://www.has-sante.fr/jcms/p_3097597/fr/kisqali
2020
false
false
false
France
antineoplastic combined chemotherapy protocols
treatment outcome
ribociclib
ribociclib
Fulvestrant/Ribociclib Regimen
Fulvestrant
postmenopause
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
breast neoplasms
survival analysis
insurance, health, reimbursement
antineoplastic agents
evaluation of the transparency committee
aminopyridines
purines

---
https://www.has-sante.fr/jcms/p_3103868/fr/kisqali
2019
false
false
false
France
breast neoplasms
antineoplastic combined chemotherapy protocols
ribociclib
ribociclib
antineoplastic agents
aromatase inhibitors
Letrozole
Anastrozole
adult
evaluation of the transparency committee
aminopyridines
purines

---
https://www.has-sante.fr/portail/jcms/c_2892921/fr/verzenios
2019
false
false
false
France
French
treatment outcome
abemaciclib
antineoplastic combined chemotherapy protocols
postmenopause
breast neoplasms
neoplasm metastasis
neoplasm recurrence, local
administration, oral
antineoplastic agents
antineoplastic agents
Hormone receptor positive malignant neoplasm of breast (disorder)
insurance, health, reimbursement
evaluation of the transparency committee
abemaciclib
abemaciclib
aminopyridines
benzimidazoles
aminopyridines
benzimidazoles

---
https://www.has-sante.fr/jcms/p_3109937/fr/orkambi
2019
false
false
false
France
ivacaftor
lumacaftor
administration, oral
treatment outcome
insurance, health, reimbursement
child
cystic fibrosis
cystic fibrosis transmembrane conductance regulator delta F508
mutation
ivacaftor and lumacaftor
evaluation of the transparency committee
lumacaftor, ivacaftor drug combination
drug combinations
quinolones
benzodioxoles
aminophenols
aminopyridines
cystic fibrosis transmembrane conductance regulator

---
Verzenios abemaciclib
https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios
2018
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
antineoplastic combined chemotherapy protocols
antineoplastic agents
antineoplastic agents
breast neoplasms
Hormone receptor positive malignant neoplasm of breast (disorder)
administration, oral
abemaciclib
product surveillance, postmarketing
food-drug interactions
drug interactions
pregnancy
Cyclin-Dependent kinase 4
Cyclin-Dependent kinase 6
protein kinase inhibitors
protein kinase inhibitors
survival analysis
drug evaluation, preclinical
Abemaciclib/Fulvestrant Regimen
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
abemaciclib
abemaciclib
aminopyridines
benzimidazoles
aminopyridines
benzimidazoles

---
https://www.inesss.qc.ca/index.php?id=72&DemandePluginController%5Buid%5D=4433&DemandePluginController%5Bonglet%5D=2&DemandePluginController%5BbackUrl%5D=%252Findex.php%253Fid%253D72%2526no_cache%253D1%2526DemandePluginController%25255Buid%25255D%253D4535%2526DemandePluginController%25255Bonglet%25255D%253D2%2526DemandePluginController%25255BbackUrl%25255D%253D%2525252Findex.php%2525253Fid%2525253D72%25252526no_cache%2525253D1%25252526DemandePluginController%252525255Buid%252525255D%2525253D4526%25252526DemandePluginController%252525255Bonglet%252525255D%2525253D2%25252526DemandePluginController%252525255BbackUrl%252525255D%2525253D%25252525252Findex.php%25252525253Fid%25252525253D72%252525252526no_cache%25252525253D1%252525252526DemandePluginController%2525252525255Buid%2525252525255D%25252525253D4469%252525252526DemandePluginController%2525252525255Bonglet%2525252525255D%25252525253D2%252525252526DemandePluginController%2525252525255BbackUrl%2525252525255D%25252525253D%252525252525252Findex.php%252525252525253Fid%252525252525253D72%2525252525252526no_cache%252525252525253D1%2525252525252526DemandePluginController%25252525252525255Buid%25252525252525255D%252525252525253D4496%2525252525252526DemandePluginController%25252525252525255Bonglet%25252525252525255D%252525252525253D2&cHash=a44ffc75b859ef1167959ab5debed264
2018
false
false
false
Canada
French
drug evaluation
canada
ozenoxacin
aminopyridines
quinolones

---
https://www.has-sante.fr/jcms/c_2827573/fr/kisqali
2018
false
false
false
France
French
treatment outcome
ribociclib
ribociclib
neoplasm metastasis
Locally Advanced Malignant Neoplasm
antineoplastic agents
antineoplastic agents
Locally advanced breast cancer
breast neoplasms
postmenopause
Stage IV Breast Cancer AJCC v6 and v7
Hormone receptor positive malignant neoplasm of breast (disorder)
administration, oral
HER2/Neu Negative
Cyclin-Dependent kinase 4
Cyclin-Dependent kinase 6
protein kinase inhibitors
protein kinase inhibitors
antineoplastic combined chemotherapy protocols
adult
aged
ribociclib
evaluation of the transparency committee
guidelines for drug use
aminopyridines
purines
aminopyridines
purines

---
https://www.has-sante.fr/portail/jcms/c_2889886/fr/orkambi
https://www.has-sante.fr/portail/jcms/c_2889886/fr/orkambi-lumacaftor-/-ivacaftor-correcteur-et-potentialisateur-du-gene-cftr
2018
false
false
false
France
French
drug combinations
aminophenols
aminopyridines
aminopyridines
aminophenols
quinolones
quinolones
benzodioxoles
benzodioxoles
adolescent
adult
CFTR gene.p.F508 del
cystic fibrosis transmembrane conductance regulator
cystic fibrosis transmembrane conductance regulator delta F508
cystic fibrosis
ivacaftor
ivacaftor
treatment outcome
ivacaftor and lumacaftor
lumacaftor, ivacaftor drug combination
lumacaftor, ivacaftor drug combination
evaluation of the transparency committee
insurance, health, reimbursement
forced expiratory volume
orphan drug production
guidelines for drug use
lumacaftor
lumacaftor
cystic fibrosis transmembrane conductance regulator

---
Summary Basis of Decision (SBD) for Ozanex
Ozenoxacin cream 1% w/w, topical
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00358
2017
false
false
false
Canada
French
drug information
ozenoxacin
administration, cutaneous
drug approval
canada
treatment outcome
ozenoxacin
anti-bacterial agents
anti-bacterial agents
impetigo
infant
child
adolescent
adult
ozenoxacin
ointments
aminopyridines
quinolones
aminopyridines
quinolones

---
https://www.ema.europa.eu/medicines/human/EPAR/Kisqali
2017
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
ribociclib
ribociclib
neoplasm metastasis
Locally Advanced Malignant Neoplasm
antineoplastic agents
antineoplastic agents
Locally advanced breast cancer
breast neoplasms
postmenopause
Hormone receptor positive malignant neoplasm of breast (disorder)
administration, oral
Cyclin-Dependent kinase 4
Cyclin-Dependent kinase 6
protein kinase inhibitors
protein kinase inhibitors
drug monitoring
product surveillance, postmarketing
antineoplastic combined chemotherapy protocols
adult
aged
drug interactions
drug evaluation, preclinical
ribociclib
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
Fulvestrant/Ribociclib Regimen
aminopyridines
purines
aminopyridines
purines

---
http://www.has-sante.fr/portail/jcms/c_2656337/fr/orkambi
http://www.has-sante.fr/portail/jcms/c_2656337/fr/orkambi-lumacaftor-/-ivacaftor-correcteur-et-potentialisateur-du-gene-cftr
2016
false
false
false
France
French
drug combinations
aminophenols
aminopyridines
aminopyridines
aminophenols
quinolones
quinolones
benzodioxoles
benzodioxoles
adolescent
adult
CFTR gene.p.F508 del
cystic fibrosis transmembrane conductance regulator
cystic fibrosis transmembrane conductance regulator delta F508
cystic fibrosis
ivacaftor
ivacaftor
treatment outcome
ivacaftor and lumacaftor
lumacaftor, ivacaftor drug combination
lumacaftor, ivacaftor drug combination
evaluation of the transparency committee
insurance, health, reimbursement
forced expiratory volume
guidelines for drug use
orphan drug production
lumacaftor
lumacaftor
cystic fibrosis transmembrane conductance regulator
drug combinations
drug combinations

---
https://www.ema.europa.eu/medicines/human/EPAR/Orkambi
2015
false
false
false
United Kingdom
French
English
summary of product characteristics
package leaflet
drug combinations
aminophenols
aminopyridines
aminopyridines
aminophenols
quinolones
quinolones
benzodioxoles
benzodioxoles
continuity of patient care
adolescent
adult
CFTR gene.p.F508 del
cystic fibrosis transmembrane conductance regulator
cystic fibrosis transmembrane conductance regulator delta F508
cystic fibrosis
ivacaftor
ivacaftor
drug evaluation
syndication feed
drug approval
europe
treatment outcome
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
product surveillance, postmarketing
ivacaftor and lumacaftor
lumacaftor, ivacaftor drug combination
lumacaftor, ivacaftor drug combination
lumacaftor
lumacaftor
cystic fibrosis transmembrane conductance regulator
drug combinations
drug combinations

---
Nous contacter.
01/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.